One study focused on FSH and Her-2 in breast cancer (32), while certain studies have revealed that FSH stimulates Her-2 expression via specific signaling pathways, including cAMP, in ovarian cancer (22,33,34). This evidence concerns the gene BRD2 and ovarian carcinoma.